Condition: Advanced Solid Tumors · Sponsor: Bristol-Myers Squibb
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0007 | Los Angeles, California, United States | Active Not Recruiting |
| Local Institution - 0017 | Grand Rapids, Michigan, United States | Active Not Recruiting |
| Local Institution - 0004 | Hackensack, New Jersey, United States | Active Not Recruiting |
| Local Institution - 0006 | Pittsburgh, Pennsylvania, United States | Active Not Recruiting |
| Tasman Oncology Research | Southport, Queensland, Australia | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06730750